These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 7515268

  • 21. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, Greco G, Buquicchio C, Liso V.
    Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
    [Abstract] [Full Text] [Related]

  • 22. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
    Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, Gatti AM, Cerri R, Celesti L, Vallebella E, Sessarego M, Patrone F, Ghio R, Damasio E, Gobbi M.
    Haematologica; 1996 Apr; 81(6):513-20. PubMed ID: 9009438
    [Abstract] [Full Text] [Related]

  • 23. Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells.
    Tosi P, Visani G, Ottaviani E, Manfori S, Zinzani PL, Tura S.
    Leukemia; 1994 Dec; 8(12):2076-82. PubMed ID: 7528855
    [Abstract] [Full Text] [Related]

  • 24. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
    Hänel M, Friedrichsen K, Hänel A, Herbst R, Morgner A, Neser S, Nicklisch M, Teich M, Ehninger G, Fiedler F.
    Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
    [Abstract] [Full Text] [Related]

  • 25. [Experience with fludarabine treatment and review of the literature].
    Telek B, Rejtó L, Kiss A, Batár P, Reményi G, Rák K, Udvardy M.
    Orv Hetil; 2002 Jun 16; 143(24):1459-65. PubMed ID: 12138643
    [Abstract] [Full Text] [Related]

  • 26. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
    Virchis A, Koh M, Rankin P, Mehta A, Potter M, Hoffbrand AV, Prentice HG.
    Br J Haematol; 2004 Jan 16; 124(1):26-32. PubMed ID: 14675405
    [Abstract] [Full Text] [Related]

  • 27. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.
    Jackson G, Taylor P, Smith GM, Marcus R, Smith A, Chu P, Littlewood TJ, Duncombe A, Hutchinson M, Mehta AB, Johnson SA, Carey P, MacKie MJ, Ganly PS, Turner GE, Deane M, Schey S, Brookes J, Tollerfield SM, Wilson MP.
    Br J Haematol; 2001 Jan 16; 112(1):127-37. PubMed ID: 11167793
    [Abstract] [Full Text] [Related]

  • 28. Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia.
    Millot F, Brice P, Philippe N, Thyss A, Demeoq F, Wetterwald M, Boccara JF, Vilque JP, Guyotat D, Guilhot J, Guilhot F.
    J Pediatr Hematol Oncol; 2002 Jan 16; 24(1):18-22. PubMed ID: 11902732
    [Abstract] [Full Text] [Related]

  • 29. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
    Kornblau SM, Cortes-Franco J, Estey E.
    Leukemia; 1993 Mar 16; 7(3):378-83. PubMed ID: 8445943
    [Abstract] [Full Text] [Related]

  • 30. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C, Regazzi E, Andrizzi C, Savoldo B, Garau D, Montefusco E, Vignetti M, Mandelli F, Rizzoli V, Meloni G.
    Haematologica; 1997 Mar 16; 82(3):291-6. PubMed ID: 9234574
    [Abstract] [Full Text] [Related]

  • 31. Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
    Hambach L, Eder M, Dammann E, Battmer K, Stucki A, Heil G, Ganser A, Hertenstein B.
    Bone Marrow Transplant; 2001 Oct 16; 28(7):705-7. PubMed ID: 11704795
    [Abstract] [Full Text] [Related]

  • 32. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
    Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM, Samaratunga IR, Grace R, Gover PA, Mufti GJ.
    Br J Haematol; 1997 Dec 16; 99(4):939-44. PubMed ID: 9432047
    [Abstract] [Full Text] [Related]

  • 33. Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study.
    Carella AM, Cascavilla N, Greco MM, Melillo L, Sajeva MR, Ladogana S, D'Arena G, Perla G, Carotenuto M.
    Leuk Lymphoma; 2001 Jan 16; 40(3-4):295-303. PubMed ID: 11426551
    [Abstract] [Full Text] [Related]

  • 34. Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect.
    Childs R, Epperson D, Bahceci E, Clave E, Barrett J.
    Br J Haematol; 1999 Nov 16; 107(2):396-400. PubMed ID: 10583233
    [Abstract] [Full Text] [Related]

  • 35. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
    Koller CA, Kantarjian HM, Feldman EJ, O'Brien S, Rios MB, Estey E, Keating M.
    Cancer; 1999 Dec 01; 86(11):2246-51. PubMed ID: 10590364
    [Abstract] [Full Text] [Related]

  • 36. [Current and new therapeutic strategies in acute myeloid leukemia].
    Naito K, Ohnishi K.
    Gan To Kagaku Ryoho; 2005 Mar 01; 32(3):292-6. PubMed ID: 15791811
    [Abstract] [Full Text] [Related]

  • 37. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 01; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 38. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
    Nakayama H, Tomizawa D, Tanaka S, Iwamoto S, Shimada A, Saito AM, Yamashita Y, Moritake H, Terui K, Taga T, Matsuo H, Kosaka Y, Koh K, Hosoi H, Kurosawa H, Isoyama K, Horibe K, Mizutani S, Adachi S.
    Pediatr Int; 2017 Oct 01; 59(10):1046-1052. PubMed ID: 28771903
    [Abstract] [Full Text] [Related]

  • 39. Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia.
    Visani G, Rosti G, Bandini G, Tosi P, Isidori A, Malagola M, Stanzani M, Martinelli G, Piccaluga P, Testoni N, Ricci P, Tura S.
    Br J Haematol; 2000 Jun 01; 109(4):722-8. PubMed ID: 10929021
    [Abstract] [Full Text] [Related]

  • 40. First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia.
    Clavio M, Gatto S, Beltrami G, Cerri R, Carrara P, Pierri I, Canepa L, Miglino M, Balleari E, Masoudi B, Damasio E, Ghio R, Sessarego M, Gobbi M.
    Leuk Lymphoma; 2001 Jan 01; 40(3-4):305-13. PubMed ID: 11426552
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.